In addition to visfatin, Gonzalez-Gay et al demonstrated rapid reduction of serum resistin [18], but not adiponectin [19] levels in patients with long-term and active RA during anti-TNF-alpha therapy with infliximab. This evidence concerns the gene TNF and rheumatoid arthritis.